SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

Virtual reality relaxation program can reduce pain intensity, with significant changes in brain functional connectivity patterns.

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

Enfortumab vedotin plus pembrolizumab is more effective than chemotherapy as first-line treatment for metastatic urothelial cancer, data suggest.

Converting from the long-acting ESA methoxy polyethylene glycol-epoetin-ß (MPG-EPO) to thrice weekly vadadustat is feasible for the hemodialysis population.

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

(HealthDay News) — Microplastic exposure may increase the risk for chronic diseases, according to a study presented at the annual meeting of the American College of Cardiology, held from March 29 to ...

(HealthDay News) — Despite increased participation in U.S. long-distance running races, cardiac arrest incidence remains stable, according to a study published online March 30 in the Journal of the ...

The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Secondary rectal cancer tumors that develop years after prostate cancer radiation therapy appear to differ in distinct ways from primary rectal cancers.

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

Clinicians should not neglect proteinuria testing in adults younger than age 40 years to identify those at high risk for sudden cardiac arrest.